ESR2 and urinary bladder carcinoma: We additionally showed that FOXO1, which could be inactivated via the ERβ pathway as described above (69), was also inactivated in cisplatin-resistant bladder cancer cells and that FOXO1 knockdown or inhibitor treatment significantly induced resistance to cisplatin in bladder cancer cells (83).